Opinions
Jim Cramer - Mad Money
Karuna Therapeutics
KRTX-Q
COMMENT
Dec 01, 2021
An early-stage biopharma, so you can't buy their drugs right now, but they are developing drugs. Their lead drug treats schizophrenia as well as psychosis. Shares are up 21% YTD, but has pulled back hard in the past month.
$123.050
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising